TAYSHA GENE THERAPIES INC. - COMMON STOCK

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

18 Jun 2024 06:30:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting

12 Jun 2024 06:00:43 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

07 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update

14 May 2024 15:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14

07 May 2024 15:05:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 May 2024 15:05:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

02 May 2024 07:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

05 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

19 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19

14 Mar 2024 15:26:51 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 Mar 2024 16:08:33 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome

29 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

15 Feb 2024 15:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

02 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference

22 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

10 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

05 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

29 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

14 Nov 2023 15:08:01 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14

07 Nov 2023 07:00:00 By Nasdaq GlobeNewswire